ERBB2 and breast cancer: Biomarker analysis from the CLEOPATRA trial demonstrated that PIK3CA mutation was associated with worse survival outcomes among patients with advanced HER2+ BC.[29] Nevertheless, the addition of pertuzumab benefited all patients, regardless of PIK3CA status.